Parallel phase I study of ixabepilone plus lapatinib and ixabepilone plus lapatinib plus capecitabine in subjects with HER2 [human epidermal growth factor receptor 2] positive locally advanced or metastatic breast cancer.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixabepilone (Primary) ; Capecitabine; Lapatinib
Indications Advanced breast cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

01 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
15 Jun 2010 Planned end date changed from 1 Feb 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight